Correction of hypomagnesemia by dapagliflozin in patients with type 2 diabetes: A post hoc analysis of 10 randomized, placebo-controlled trials

Robert D Toto, Ronald Goldenberg, Glenn M. Chertow, Valerie Cain, Bergur V. Stefánsson, C. David Sjöström, P. Sartipy

Research output: Contribution to journalArticle

Abstract

Aims: Hypomagnesemia (serum magnesium [Mg] <0.74 mmol/L [<1.8 mg/dL]) is commonly observed in patients with type 2 diabetes (T2D). This study investigated the effect of treatment with dapagliflozin 10 mg on Mg concentrations in patients with T2D. Methods: In this post hoc analysis, we used pooled data from 10 placebo-controlled studies of dapagliflozin over 24 weeks of treatment in patients with T2D. We evaluated the change in Mg in patients receiving dapagliflozin vs. placebo overall, and in subgroups with baseline hypomagnesemia and normal/hypermagnesemia (≥0.74 mmol/L [≥1.8 mg/dL]). We determined the proportion of patients with baseline hypomagnesemia who achieved Mg ≥0.74 mmol/L (≥1.8 mg/dL). Results: A total of 4398 patients with T2D were included. The mean change from baseline to week 24 in Mg was significantly larger with dapagliflozin vs. placebo; difference, 0.06 mmol/L (95% confidence interval [CI]: 0.05, 0.06). The proportion of patients with Mg within the population reference range after 24 weeks of treatment was significantly higher with dapagliflozin vs. placebo; difference, 47.8% (95% CI: 41.4, 53.9). The proportion of patients displaying hypermagnesemia did not increase with dapagliflozin treatment. Conclusions: Treatment with dapagliflozin 10 mg resulted in correction of Mg concentrations in patients with T2D and hypomagnesemia.

Original languageEnglish (US)
Article number107402
JournalJournal of Diabetes and its Complications
DOIs
StatePublished - Jan 1 2019

Fingerprint

Type 2 Diabetes Mellitus
Randomized Controlled Trials
Placebos
Magnesium
Confidence Intervals
Therapeutics
2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol
Reference Values
Serum
Population

Keywords

  • Dapagliflozin
  • Hypomagnesemia
  • Post hoc analysis
  • Randomized controlled trials
  • SGLT2 inhibitor
  • Type 2 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Correction of hypomagnesemia by dapagliflozin in patients with type 2 diabetes : A post hoc analysis of 10 randomized, placebo-controlled trials. / Toto, Robert D; Goldenberg, Ronald; Chertow, Glenn M.; Cain, Valerie; Stefánsson, Bergur V.; Sjöström, C. David; Sartipy, P.

In: Journal of Diabetes and its Complications, 01.01.2019.

Research output: Contribution to journalArticle

Toto, Robert D ; Goldenberg, Ronald ; Chertow, Glenn M. ; Cain, Valerie ; Stefánsson, Bergur V. ; Sjöström, C. David ; Sartipy, P. / Correction of hypomagnesemia by dapagliflozin in patients with type 2 diabetes : A post hoc analysis of 10 randomized, placebo-controlled trials. In: Journal of Diabetes and its Complications. 2019.
@article{77f4ad07be7b423bb4451a4c368da88b,
title = "Correction of hypomagnesemia by dapagliflozin in patients with type 2 diabetes: A post hoc analysis of 10 randomized, placebo-controlled trials",
abstract = "Aims: Hypomagnesemia (serum magnesium [Mg] <0.74 mmol/L [<1.8 mg/dL]) is commonly observed in patients with type 2 diabetes (T2D). This study investigated the effect of treatment with dapagliflozin 10 mg on Mg concentrations in patients with T2D. Methods: In this post hoc analysis, we used pooled data from 10 placebo-controlled studies of dapagliflozin over 24 weeks of treatment in patients with T2D. We evaluated the change in Mg in patients receiving dapagliflozin vs. placebo overall, and in subgroups with baseline hypomagnesemia and normal/hypermagnesemia (≥0.74 mmol/L [≥1.8 mg/dL]). We determined the proportion of patients with baseline hypomagnesemia who achieved Mg ≥0.74 mmol/L (≥1.8 mg/dL). Results: A total of 4398 patients with T2D were included. The mean change from baseline to week 24 in Mg was significantly larger with dapagliflozin vs. placebo; difference, 0.06 mmol/L (95{\%} confidence interval [CI]: 0.05, 0.06). The proportion of patients with Mg within the population reference range after 24 weeks of treatment was significantly higher with dapagliflozin vs. placebo; difference, 47.8{\%} (95{\%} CI: 41.4, 53.9). The proportion of patients displaying hypermagnesemia did not increase with dapagliflozin treatment. Conclusions: Treatment with dapagliflozin 10 mg resulted in correction of Mg concentrations in patients with T2D and hypomagnesemia.",
keywords = "Dapagliflozin, Hypomagnesemia, Post hoc analysis, Randomized controlled trials, SGLT2 inhibitor, Type 2 diabetes",
author = "Toto, {Robert D} and Ronald Goldenberg and Chertow, {Glenn M.} and Valerie Cain and Stef{\'a}nsson, {Bergur V.} and Sj{\"o}str{\"o}m, {C. David} and P. Sartipy",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.jdiacomp.2019.06.007",
language = "English (US)",
journal = "Journal of Diabetes and its Complications",
issn = "1056-8727",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Correction of hypomagnesemia by dapagliflozin in patients with type 2 diabetes

T2 - A post hoc analysis of 10 randomized, placebo-controlled trials

AU - Toto, Robert D

AU - Goldenberg, Ronald

AU - Chertow, Glenn M.

AU - Cain, Valerie

AU - Stefánsson, Bergur V.

AU - Sjöström, C. David

AU - Sartipy, P.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Aims: Hypomagnesemia (serum magnesium [Mg] <0.74 mmol/L [<1.8 mg/dL]) is commonly observed in patients with type 2 diabetes (T2D). This study investigated the effect of treatment with dapagliflozin 10 mg on Mg concentrations in patients with T2D. Methods: In this post hoc analysis, we used pooled data from 10 placebo-controlled studies of dapagliflozin over 24 weeks of treatment in patients with T2D. We evaluated the change in Mg in patients receiving dapagliflozin vs. placebo overall, and in subgroups with baseline hypomagnesemia and normal/hypermagnesemia (≥0.74 mmol/L [≥1.8 mg/dL]). We determined the proportion of patients with baseline hypomagnesemia who achieved Mg ≥0.74 mmol/L (≥1.8 mg/dL). Results: A total of 4398 patients with T2D were included. The mean change from baseline to week 24 in Mg was significantly larger with dapagliflozin vs. placebo; difference, 0.06 mmol/L (95% confidence interval [CI]: 0.05, 0.06). The proportion of patients with Mg within the population reference range after 24 weeks of treatment was significantly higher with dapagliflozin vs. placebo; difference, 47.8% (95% CI: 41.4, 53.9). The proportion of patients displaying hypermagnesemia did not increase with dapagliflozin treatment. Conclusions: Treatment with dapagliflozin 10 mg resulted in correction of Mg concentrations in patients with T2D and hypomagnesemia.

AB - Aims: Hypomagnesemia (serum magnesium [Mg] <0.74 mmol/L [<1.8 mg/dL]) is commonly observed in patients with type 2 diabetes (T2D). This study investigated the effect of treatment with dapagliflozin 10 mg on Mg concentrations in patients with T2D. Methods: In this post hoc analysis, we used pooled data from 10 placebo-controlled studies of dapagliflozin over 24 weeks of treatment in patients with T2D. We evaluated the change in Mg in patients receiving dapagliflozin vs. placebo overall, and in subgroups with baseline hypomagnesemia and normal/hypermagnesemia (≥0.74 mmol/L [≥1.8 mg/dL]). We determined the proportion of patients with baseline hypomagnesemia who achieved Mg ≥0.74 mmol/L (≥1.8 mg/dL). Results: A total of 4398 patients with T2D were included. The mean change from baseline to week 24 in Mg was significantly larger with dapagliflozin vs. placebo; difference, 0.06 mmol/L (95% confidence interval [CI]: 0.05, 0.06). The proportion of patients with Mg within the population reference range after 24 weeks of treatment was significantly higher with dapagliflozin vs. placebo; difference, 47.8% (95% CI: 41.4, 53.9). The proportion of patients displaying hypermagnesemia did not increase with dapagliflozin treatment. Conclusions: Treatment with dapagliflozin 10 mg resulted in correction of Mg concentrations in patients with T2D and hypomagnesemia.

KW - Dapagliflozin

KW - Hypomagnesemia

KW - Post hoc analysis

KW - Randomized controlled trials

KW - SGLT2 inhibitor

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=85069912043&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069912043&partnerID=8YFLogxK

U2 - 10.1016/j.jdiacomp.2019.06.007

DO - 10.1016/j.jdiacomp.2019.06.007

M3 - Article

C2 - 31375422

AN - SCOPUS:85069912043

JO - Journal of Diabetes and its Complications

JF - Journal of Diabetes and its Complications

SN - 1056-8727

M1 - 107402

ER -